Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Xin Huang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0359-7290; OpenAlex author ID A5032720475. Sources: OpenAlex.

Their work

Papers
16 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2018: 1 paper · 2019: 1 paper · 2020: 7 papers · 2021: 2 papers · 2022: 1 paper · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 16

  1. TGFβ2 Promotes the Construction of Fibrotic and Immunosuppressive Tumor Microenvironment in Pancreatic Adenocarcinoma: A Comprehensive Analysis. Co-author DOI 10.1007/s12033-024-01219-1↗
  2. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer [Cancer Lett. 502 (2021) 9-24]. Co-author DOI 10.1016/j.canlet.2024.216697↗
  3. Treatment of locally advanced pancreatic cancer with irreversible electroporation and intraoperative radiotherapy. First author DOI 10.21037/hbsn-24-526↗
  4. Establishment and validation of a prognostic signature for pancreatic ductal adenocarcinoma based on lactate metabolism-related genes. Co-author DOI 10.3389/fmolb.2023.1143073↗
  5. An Inflammatory Response-Related Gene Signature Reveals Distinct Survival Outcome and Tumor Microenvironment Characterization in Pancreatic Cancer. First author DOI 10.3389/fmolb.2022.876607↗
  6. Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2020.12.018↗
  7. The impact of different metastatic patterns on survival in patients with pancreatic cancer. First author DOI 10.1016/j.pan.2021.01.014↗
  8. T-cell activation and immune memory enhancement induced by irreversible electroporation in pancreatic cancer. First author DOI 10.1002/ctm2.39↗
  9. Oxidative stress induces monocyte-to-myofibroblast transdifferentiation through p38 in pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ctm2.41↗
  10. Induced CD10 expression during monocyte-to-macrophage differentiation identifies a unique subset of macrophages in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbrc.2020.02.042↗
  11. Comparison of Survival Between Irreversible Electroporation Followed by Chemotherapy and Chemotherapy Alone for Locally Advanced Pancreatic Cancer. First author DOI 10.3389/fonc.2020.00006↗
  12. A Novel Prediction Tool Based on Large Cohorts to Determine the Cancer-Specific Survival Probability of Patients With Locally Advanced Pancreatic Cancer After … First author DOI 10.3389/fonc.2020.00952↗
  13. SYPL1 Inhibits Apoptosis in Pancreatic Ductal Adenocarcinoma via Suppression of ROS-Induced ERK Activation. Co-author DOI 10.3389/fonc.2020.01482↗
  14. Survival Comparison of Neoadjuvant Chemotherapy Followed by Irreversible Electroporation Versus Conversional Resection for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3389/fonc.2020.622318↗
  15. A Quantitative Clinicopathological Signature for Predicting Recurrence Risk of Pancreatic Ductal Adenocarcinoma After Radical Resection. First author DOI 10.3389/fonc.2019.01197↗
  16. A Refined Staging Model for Resectable Pancreatic Ductal Adenocarcinoma Incorporating Examined Lymph Nodes, Location of Tumor and Positive Lymph Nodes Ratio. Co-author DOI 10.7150/jca.26187↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shengping Li · 14 shared papers, 2018–2024 · strength 2.00
  2. Chaobin He · 13 shared papers, 2018–2024 · strength 1.74
  3. Xiaojun Lin · 6 shared papers, 2019–2021 · strength 0.85
  4. Shuxin Sun · 6 shared papers, 2020–2024 · strength 0.74
  5. Fengxiao Xie · 4 shared papers, 2020–2024 · strength 0.59
  6. Jun Wang · 4 shared papers, 2018–2024 · strength 0.48
  7. Yize Mao · 3 shared papers, 2020 · strength 0.31
  8. Guangmei Yan · 2 shared papers, 2021–2024 · strength 0.29
  9. Jing Cai · 2 shared papers, 2021–2024 · strength 0.29
  10. Yunda Song · 3 shared papers, 2018–2020 · strength 0.29
  11. Lingmin Jiang · 1 shared paper, 2024 · strength 0.24
  12. Shengping Li · 1 shared paper, 2024 · strength 0.24
  13. Xiao-fen Yu · 1 shared paper, 2025 · strength 0.23
  14. Xiaoping Zhong · 1 shared paper, 2025 · strength 0.23
  15. Peng Huang · 1 shared paper, 2020 · strength 0.11
  16. Xiang‐Ming Lao · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.